Cilostazol and Ginkgo for improving cognitive function in elderly with diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory pilot study evaluates the cognitive improvement effects of a combination therapy using cilostazol and ginkgo biloba extract in elderly patients diagnosed with type 2 diabetes mellitus. The study aims to determine if this combination can enhance cerebral blood flow and provide neuroprotection, potentially preventing cognitive decline. Participants will receive either the active treatment or a placebo, and their cognitive abilities will be assessed using standardized measures. The findings may lay the groundwork for future therapeutic strategies targeting cognitive impairment in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with type 2 diabetes mellitus
* Adults aged 60 years or older
* Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months

Exclusion Criteria:

* Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma
* Patients with poorly controlled blood glucose (HbA1c \> 10.0%)
* Patients with an MMSE score below 24
* Patients diagnosed with dementia (e.g., Alzheimer's disease)
* Patients with suspected cognitive impairment due to other causes
* Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
* Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
* Patients with severe depression
* Patients with severe infections, recent surgery (perioperative status), or major trauma
* Patients with pituitary or adrenal insufficiency
* Patients with other medical conditions requiring hospitalization
* Patients with a history of alcohol or drug abuse within 1 year prior to screening
* Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
* Patients deemed by the investigator to be otherwise unsuitable for study participation

Where it's running

• Seoul National University Bundang Hospital
  Seongnam-si, South Korea Recruiting

Study contacts

• Study coordinator: Soo Lim Dr., MD PhD
• Email: limsoo@snu.ac.kr
• Phone: +82-31-787-7035

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sage Extract and Memory in Middle-Aged Adults

  This study tests whether sage extract can improve thinking speed and mental sharpness in adults aged 40–60.

  Recruiting ESM Technologies, LLC · College Station, Texas · NCT07757529

• Automated Sensing of IADLs to Measure Daily Activity in Older Adults

  This study tests whether wearables, computer vision, and eye tracking can recognize everyday tasks like cooking and cleaning and compare the results with occupational therapists’ ratings in older adults living at home.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07585864

• Effects of beef consumption on brain health and cognitive function

  This study is testing how eating different amounts of beef affects brain health and thinking skills in healthy young adults aged 19 to 24.

  Recruiting University of Nebraska Lincoln · Lincoln, Nebraska · NCT06690892

• Evaluating Red Blood Cell Transfusion in ECMO Patients

  This study is trying to find the best hemoglobin levels for red blood cell transfusions in critically ill patients on ECMO to improve their care and outcomes.

  Recruiting at 2 sites Australian and New Zealand Intensive Care Research Centre · Camperdown, New South Wales and 1 other locations · NCT05814094

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.